Skip to main content

SA Im

First name:
SA
Last name:
Im
Koh, Y. ., Lee, H. ., Im, S. ., Kim, S. ., Kim, T. ., Han, S. ., … Bang, Y. . (1969). VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib. Diagnostic Molecular Pathology : The American Journal of Surgical Pathology, Part B. https://doi.org/10.1097/PDM.0b013e3182107ea0 (Original work published)
Turner, N. ., Finn, R. ., Martin, M. ., Im, S. ., DeMichele, A. ., Ettl, J. ., … Gelmon, K. . (2018). Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases. Annals of Oncology : Official Journal of the European Society for Medical Oncology. https://doi.org/10.1093/annonc/mdx797 (Original work published 2018)
Pivot, X. ., Bondarenko, I. ., Nowecki, Z. ., Dvorkin, M. ., Trishkina, E. ., Ahn, J. ., … Lim, J. . (2018). Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive.. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017740126. https://doi.org/10.1200/JCO.2017.74.0126 (Original work published 2018)
Kim, S. ., Dent, R. ., Im, S. ., Espié, M. ., Blau, S. ., Tan, A. ., … LOTUS, investigators. . (2017). Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology, 18(10), 1360-1372. https://doi.org/10.1016/S1470-2045(17)30450-3